Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4773715 | 0.98 | GBA1 (0.58) | GBA1HTR2CSLC6A2SLC6A4CACNA1H | |
| Hydrochloric Acid SCHEMBL22462991 | 0.92 | GBA1 (0.51) | GBA1HTR2CSLC6A2SLC6A4CACNA1H | |
| SCHEMBL6922709 | 0.91 | GBA1 (0.50) | GBA1HTR2CSLC6A2SLC6A4CACNA1H | |
| SCHEMBL28933802 | 0.90 | HTR2C (0.49) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL8227791 | 0.90 | HTR2C (0.49) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| Hydrochloric Acid SCHEMBL23632761 | 0.88 | HTR2C (0.50) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL13279963 | 0.87 | MAOB (0.55) | GBA1HTR2C | |
| SCHEMBL13957365 | 0.87 | TEAD1 (0.51) | HTR2CSLC6A2SLC6A4RPS6KB1TEAD1 | |
| SCHEMBL9562394 | 0.84 | MAOB (0.55) | HTR2CSLC6A2SLC6A4 | |
| SCHEMBL6721394 | 0.83 | RPS6KB1 (0.47) | SLC6A2SLC6A4RPS6KB1TEAD1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-1089735-A4 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6448270-B1 | BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA | WARNER-LAMBERT COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6284774-B1 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-09-04 | — | — | US | disclosed |
| CN-1304307-A | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists | WARNER LAMBER CO (US) | 2001-07-18 | — | — | CN | disclosed |
| EP-1089735-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000000197-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | GBA1 33/4885HTR2C 1389/4885SLC6A2 4083/4885 |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | GBA1 33/4885HTR2C 3324/4885SLC6A2 4711/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GBA1 39/4885HTR2C 2531/4885SLC6A2 4730/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GBA1 39/4885HTR2C 2531/4885SLC6A2 4730/4885 |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GBA1 209/4885HTR2C 2900/4885SLC6A2 2043/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | GBA1 1415/4885HTR2C 787/4885SLC6A2 3743/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GBA1 39/4885HTR2C 2531/4885SLC6A2 4730/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GBA1 39/4885HTR2C 2531/4885SLC6A2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.